Connection

Alessandro Rambaldi to Prognosis

Back to Details
This is a "connection" page, showing publications Alessandro Rambaldi has written about Prognosis.
Alessandro Rambaldi
Connection Strength
0.246
Prognosis
  1. High mortality rate in COVID-19 patients with myeloproliferative neoplasms after abrupt withdrawal of ruxolitinib. Leukemia. 2021 02; 35(2):485-493.
    View in: PubMed
    Score: 0.041
  2. Phase II Study of Sequential Infusion of Donor Lymphocyte Infusion and Cytokine-Induced Killer Cells for Patients Relapsed after Allogeneic Hematopoietic Stem Cell Transplantation. Biol Blood Marrow Transplant. 2017 Dec; 23(12):2070-2078.
    View in: PubMed
    Score: 0.032
  3. Inflammation and myeloproliferative neoplasms. J Autoimmun. 2017 Dec; 85:58-63.
    View in: PubMed
    Score: 0.032
  4. Detection of driver and subclonal mutations in myelofibrosis: clinical impact on pharmacologic and transplant based treatment strategies. Expert Rev Hematol. 2017 07; 10(7):627-636.
    View in: PubMed
    Score: 0.032
  5. Driver mutations (JAK2V617F, MPLW515L/K or CALR), pentraxin-3 and C-reactive protein in essential thrombocythemia and polycythemia vera. J Hematol Oncol. 2017 02 22; 10(1):54.
    View in: PubMed
    Score: 0.031
  6. Macrophage expression and prognostic significance of the long pentraxin PTX3 in COVID-19. Nat Immunol. 2021 01; 22(1):19-24.
    View in: PubMed
    Score: 0.010
  7. COVID-19 severity and mortality in patients with chronic lymphocytic leukemia: a joint study by ERIC, the European Research Initiative on CLL, and CLL Campus. Leukemia. 2020 09; 34(9):2354-2363.
    View in: PubMed
    Score: 0.010
  8. Gender effect on phenotype and genotype in patients with post-polycythemia vera and post-essential thrombocythemia myelofibrosis: results from the MYSEC project. Blood Cancer J. 2018 09 21; 8(10):89.
    View in: PubMed
    Score: 0.009
  9. Value of cytogenetic abnormalities in post-polycythemia vera and post-essential thrombocythemia myelofibrosis: a study of the MYSEC project. Haematologica. 2018 09; 103(9):e392-e394.
    View in: PubMed
    Score: 0.008
  10. MIPSS70: Mutation-Enhanced International Prognostic Score System for Transplantation-Age Patients With Primary Myelofibrosis. J Clin Oncol. 2018 02 01; 36(4):310-318.
    View in: PubMed
    Score: 0.008
  11. Symptom burden profile in myelofibrosis patients with thrombocytopenia: Lessons and unmet needs. Leuk Res. 2017 12; 63:34-40.
    View in: PubMed
    Score: 0.008
  12. TP53 in adult acute lymphoblastic leukemia. Leuk Lymphoma. 2018 04; 59(4):778-789.
    View in: PubMed
    Score: 0.008
  13. CEBPA-double-mutated acute myeloid leukemia displays a unique phenotypic profile: a reliable screening method and insight into biological features. Haematologica. 2017 03; 102(3):529-540.
    View in: PubMed
    Score: 0.008
  14. Prognostic impact of bone marrow fibrosis in primary myelofibrosis. A study of the AGIMM group on 490 patients. Am J Hematol. 2016 09; 91(9):918-22.
    View in: PubMed
    Score: 0.008
Connection Strength

The connection strength for concepts is the sum of the scores for each matching publication.

Publication scores are based on many factors, including how long ago they were written and whether the person is a first or senior author.